Abstract:Background: Working memory impairment is a common non-motor symptom in the progression of Parkinson's disease (PD). Ginsenoside Rb1, an extract from the Ginseng root, has been demonstrated to ameliorate motor deficits and prevent dopaminergic neuron death in PD. However, whether Rb1 can attenuate the PD-associated deficits in working memory and its underlying mechanism of action are still unclear. Methods: Behavioral tests were used to examine the effect of Rb1 on the working memory deficits in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD. Gamma-aminobutyric acid (GABA)-chemical exchange saturation transfer (CEST) magnetic resonance imaging and electrophysiology were used to identify the effect of Rb1 on the GABA content and GABAergic synaptic transmission in the prefrontal cortex. Immunofluorescence and western blotting were used to explore the expression of the different GABA receptors. Findings: We found that Rb1 attenuated the impairment in spatial working memory in the MPTP mouse model of PD, and this neuroprotective mechanism involved the regulation of prefrontal cortical GABAergic content and transmission. We demonstrated that Rb1 increased GABA content in the prefrontal cortex, and Rb1 prevented the MPTP-induced decrease of presynaptic GABA release and postsynaptic GABA receptor expression and function. Furthermore, Rb1's promotion of GABA current may be associated with the regulation of GABAA receptor trafficking from the postsynaptic density to the membrane, as well as with the modulation of postsynaptic GABAB receptors to enhance GABAA receptor function. Interpretation: Rb1 may serve as a potential drug candidate for the treatment of cognitive impairments in PD. Funding: The National Natural Science Foundation of China (No. 81704130 to YZ, No. 81774377 and No. 81373999 to LW), the Natural Science Foundation of Fujian Province of China (No. 2017J05139 to YZ), the Natural Science Foundation of Guangdong Province of China (No. 2017A030310643 to YZ), the China Postdoctoral Science Foundation (No. 2016M590598 to YZ), the National Key Research and Development Program of China (No. 2016YFC1305903 to LW), and the Program for New Century Excellent Talents in University of Ministry of Education of China (No. NCET-13-0505 to LW). Declaration of Interest: The authors declare no conflicts of interest. Ethical Approval: All experiments were conducted according to the National Institute of Health guidelines on the care and use of animals (NIH Publications No. 8023, revised 1978) and approved by the Institutional Animal Care and Use Committee of Guangzhou Medical University.

Ginsenoside Rb1 Ameliorates Working Memory Deficits Via Regulation of Prefrontal Cortical Gabaergic Transmission in MPTP-Treated Mice

Ginsenoside Rb1 regulates prefrontal cortical GABAergic transmission in MPTP-treated mice.

Ginsenoside Rb1 promotes glutamate transporters and plays neuroprotective roles in Parkinson's disease model

Ginsenoside Rb1 confers neuroprotection via promotion of glutamate transporters in a mouse model of Parkinson's disease.

Ginsenoside Rg1 Ameliorates Motor Function in an Animal Model of Parkinson's Disease

Protective effect of ginsenoside Rb1 against chronic restraint stress (CRS)-induced memory impairments in rats

Ginsenoside Rg1 Attenuates Motor Impairment and Neuroinflammation in the MPTP-probenecid-induced Parkinsonism Mouse Model by Targeting Α-Synuclein Abnormalities in the Substantia Nigra.

Ginsenoside RK1 improves cognitive impairments and pathological changes in Alzheimer's disease via stimulation of the AMPK/Nrf2 signaling pathway

Ginsenoside Rb1 Improves Spatial Learning and Memory by Regulation of Cell Genesis in the Hippocampal Subregions of Rats

Ginsenoside Rg1 ameliorates stress-exacerbated Parkinson's disease in mice by eliminating RTP801 and α-synuclein autophagic degradation obstacle

Ginsenoside Rg1 Ameliorates Behavioral Abnormalities and Modulates the Hippocampal Proteomic Change in Triple Transgenic Mice of Alzheimer's Disease

Ginsenoside Rg5 Improves Cognitive Dysfunction and Beta-Amyloid Deposition in STZ-induced Memory Impaired Rats Via Attenuating Neuroinflammatory Responses.

Protection Induced By Ginsenoside Rb1 in Alzheimer’s Disease Model is Associated With Redressing The Neuronal Hyperexcitability Which is Regulated By Nav1.2 and Nav1.6

Ginsenoside Rg1 alleviates learning and memory impairments and Aβ disposition through inhibiting NLRP1 inflammasome and autophagy dysfunction in APP/PS1 mice

Ginseng Improves Cognitive Deficit Via the RAGE/NF-κB Pathway in Advanced Glycation End Product-Induced Rats

Ginsenoside Rg1 in neurological diseases: From bench to bedside

Protopanaxadiols Eliminate Behavioral Impairments and Mitochondrial Dysfunction in Parkinson’s Disease Mice Model

Ginsenoside Rg1 Ameliorates Alzheimer's Disease Pathology Via Restoring Mitophagy

Protective effects of ginsenosides Rg1 and Rb1 against cognitive impairment induced by simulated microgravity in rats

Orally Administered Ginkgolide C Alleviates MPTP-Induced Neurodegeneration by Suppressing Neuroinflammation and Oxidative Stress through Microbiota-Gut-Brain Axis in Mice

Long-term ginsenoside administration prevents memory impairment in aged C57BL/6J mice by up-regulating the synaptic plasticity-related proteins in hippocampus.